JP2003210136A - Method for producing health nutritive food - Google Patents

Method for producing health nutritive food

Info

Publication number
JP2003210136A
JP2003210136A JP2002014512A JP2002014512A JP2003210136A JP 2003210136 A JP2003210136 A JP 2003210136A JP 2002014512 A JP2002014512 A JP 2002014512A JP 2002014512 A JP2002014512 A JP 2002014512A JP 2003210136 A JP2003210136 A JP 2003210136A
Authority
JP
Japan
Prior art keywords
fermentation
health
food
medium
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002014512A
Other languages
Japanese (ja)
Other versions
JP3902015B2 (en
Inventor
Hikozo Ibuki
彦三 伊吹
Kenji Goto
謙治 後藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENZAMIN KENKYUSHO KK
Original Assignee
ENZAMIN KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENZAMIN KENKYUSHO KK filed Critical ENZAMIN KENKYUSHO KK
Priority to JP2002014512A priority Critical patent/JP3902015B2/en
Publication of JP2003210136A publication Critical patent/JP2003210136A/en
Application granted granted Critical
Publication of JP3902015B2 publication Critical patent/JP3902015B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for producing liquid health nutritive food that can produce a liquid health nutritive food that can exactly develop health care action by selecting a strain that can efficiently assimilate a substrate as a fermentation microorganism. <P>SOLUTION: A saccharide prepared by hydrolyzing starch including corn starch with amylase is used as the substrate for a culture medium, to which vegetable juices and yeast as nitrogen sauces are added to prepare the culture medium for the fermentation. The culture medium is inoculated with a fermentation speed including Bacillus subtilis AK (FERM P-18291) (Bacillus natto) and a lactic acid bacterium, fermented and ripened. Then, the formed liquid component is separated as a food concentrate. The prescribed Bacillus natto efficiently assimilates saccharides and the nitrogen source in the prescribed fermentation medium to produce a variety of amino acids, lipoproteins, lipopolysaccharides, lipids, and the like, having a variety of activities. <P>COPYRIGHT: (C)2003,JPO

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】この発明は、健康増進に良い
影響をもたらす食品である保健栄養食品の製造方法に関
する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing a health and nutrition food, which is a food that has a positive effect on health promotion.

【0002】[0002]

【従来の技術】ヒトの健康を増進させる保健栄養食品と
して、生体に必要な諸成分を体内で効率よく生成するよ
うに代謝活性を高めると共に、Tリンパ球を幼若化させ
て免疫機能を増強する作用があると考えられている発酵
代謝物エキスとしてエンザミン(商品名)が周知であ
り、その製造方法が特開昭54−160787号公報に
開示されている。
2. Description of the Related Art As a health and nutritional food for promoting human health, it enhances metabolic activity so that various components necessary for the living body can be efficiently produced in the body and at the same time, immunizes the immune function by blasting T lymphocytes. Enzamine (trade name) is well-known as a fermented metabolite extract which is considered to have the above-mentioned action, and its production method is disclosed in JP-A-54-160787.

【0003】同公報によると、生体内代謝調節活性因子
を含む飲料原液は、イエローコンスターチをアミラーゼ
で充分に消化させた後、パン酵母と野菜の圧搾汁を混ぜ
て高圧殺菌し、冷却した培地を用い、この培地に、訓化
した納豆菌や、麹菌、乳酸菌などの発酵菌を接種して恒
温状態で2ヶ月以上発酵させ、さらに6ヶ月以上熟成さ
せて、透明化した濾液を分取することにより製造するこ
とができる。
[0003] According to the same publication, a beverage stock solution containing an in vivo metabolic regulation factor is prepared by sufficiently digesting yellow corn starch with amylase, then squeezing baker's yeast and vegetable squeezed juice under high pressure, and cooling the medium. Using this medium, inoculate the fermented bacteria such as cultivated Bacillus natto, koji mold, lactic acid bacteria, etc., ferment at constant temperature for 2 months or more, ripen for 6 months or more, and collect the clarified filtrate. Can be manufactured by.

【0004】[0004]

【発明が解決しようとする課題】しかし、上記した従来
の保健栄養食品の製造方法では、発酵性菌類として基材
を効率よく資化するものが開示されていないために、生
産効率が充分に高くなく、保健作用が確実に発揮される
栄養食品が効率よく製造できないという問題点がある。
However, in the above-mentioned conventional method for producing a health and nutrition food, since there is no disclosure of fermentative fungi that efficiently assimilate the substrate, the production efficiency is sufficiently high. However, there is a problem in that a nutritional food that reliably exerts health effects cannot be efficiently produced.

【0005】そこで、この発明の課題は、上記した問題
点を解決して、発酵性菌類として効率よく基材を資化す
る菌株を採用し、また保健作用をより確実に発揮する保
健栄養食品の製造方法にすることである。
Therefore, an object of the present invention is to solve the above-mentioned problems, to employ a strain that efficiently assimilates a base material as a fermentative fungus, and to provide a health and nutrition food that more reliably exerts its health action. It is a manufacturing method.

【0006】[0006]

【課題を解決するための手段】上記の課題を解決するた
め、この発明では、コーンスターチを含む澱粉をアミラ
ーゼで加水分解した糖化物を培地用基材とし、これに野
菜汁および窒素源としてイーストを添加して発酵用培地
を調整し、この培地に納豆菌であるバチルスズブチリス
AK(FERM P−18291)および乳酸菌を含
む発酵菌を接種し、発酵および熟成させた後、生成した
液状成分を分取して食品用原液とすることからなる保健
栄養食品の製造方法としたのである。
In order to solve the above problems, according to the present invention, a saccharified product obtained by hydrolyzing starch containing corn starch with amylase is used as a medium substrate, and vegetable juice and yeast as a nitrogen source are added to the medium. The fermentation medium was adjusted by addition, and fermented bacteria containing Bacillus subtilis AK (FERM P-18291) and lactic acid bacteria, which are Bacillus natto, were inoculated into this medium, fermented and aged, and then the produced liquid component was collected. Then, a method for producing a health and nutrition food, which comprises preparing an undiluted solution for food, was adopted.

【0007】上記したように構成されるこの発明の製造
方法によると、所定の発酵用培地で所定の納豆菌が効率
よく糖および窒素源を資化し、発酵生産物として各種の
活性を有するアミノ酸、リポ蛋白、リポ多糖(リポポリ
サッカライド)、リピッドなどを生成する。このように
して得られるアミノ酸(ショートペプチド)等は、生体
内細胞調整のために活性を有する因子となるものを多く
含んでいると考えられ、後述の実験結果からも明らかな
ように、抗糖尿病性(インシュリン分泌促進性)、高血
圧抑制性(アンギオテンシン変換酵素の阻害性)、免疫
向上性(ムコ多糖類によるTリンパ球の活性化)、ダイ
エット効果(糖吸収抑制と脂質代謝促進性)、抗菌性が
確実に発揮されるものと認められる。
According to the production method of the present invention configured as described above, the amino acid having various activities as a fermentation product, in which the predetermined Bacillus natto efficiently assimilates sugar and nitrogen source in the predetermined fermentation medium, It produces lipoproteins, lipopolysaccharides (lipopolysaccharides), and lipids. The amino acids (short peptides) and the like thus obtained are considered to contain a large number of factors that are active for regulating cells in vivo, and as is clear from the experimental results described below, antidiabetic (Insulin secretagogue), hypertension suppressant (angiotensin converting enzyme inhibitor), immune enhancing (mucopolysaccharide activation of T lymphocytes), diet effect (sugar absorption suppressant and lipid metabolism promoting), antibacterial It is recognized that the sex is surely exhibited.

【0008】そして、バチルス ズブチリス AKは、
コーンスターチを含む澱粉をアミラーゼで加水分解した
糖化物を基材とし、これに野菜汁および窒素源としてイ
ーストを添加した発酵用培地で効率よく増殖するもので
あり、通常の納豆菌に比べて紫外線やX線が照射された
り、競合する乳酸菌が存在したり、高・低温環境などの
過酷な環境や条件下でも生育する耐性を備えており、変
異株または亜種と見られる性質がある。
And Bacillus subtilis AK,
A starch-containing starch containing corn starch is hydrolyzed with amylase as a base material, and it grows efficiently in a fermentation medium in which yeast is added as a vegetable juice and nitrogen source. It is resistant to growth by X-ray irradiation, the presence of competing lactic acid bacteria, and even in severe environments and conditions such as high and low temperature environments, and it has the property of being seen as a mutant strain or subspecies.

【0009】保健作用をより確実に発揮する保健栄養食
品を製造するためには、バチルスズブチリス AK及び
乳酸菌を含む発酵菌による発酵条件は、pH4.5〜
6.5、28〜32℃の条件で2ヶ月以上発酵させるこ
とが好ましく、熟成条件は、pH4.0〜6.0、13
〜17℃の条件で4ヶ月以上熟成させることが好まし
い。
In order to produce a health and nutrition food that more reliably exerts health effects, the fermentation conditions for fermenting bacteria containing Bacillus tin butyris AK and lactic acid bacteria are from pH 4.5 to
It is preferable to ferment under conditions of 6.5 and 28 to 32 ° C. for 2 months or more, and aging conditions are pH 4.0 to 6.0 and 13
It is preferable to age for 4 months or more under the condition of -17 ° C.

【0010】[0010]

【発明の実施の形態】培地用基材として用いる糖化物
は、コーンスターチを含む澱粉をアミラーゼで加水分解
したものであり、コーンスターチはとうもろこし(子
実)から蛋白質を分離し、精製したものであるが、粗精
製のイエローコーンスターチを使用することがより好ま
しい。コーンスターチ以外の澱粉としては、大豆、米糠
などを採用することができる。
BEST MODE FOR CARRYING OUT THE INVENTION The saccharified product used as a substrate for a medium is a starch containing corn starch hydrolyzed with amylase, and corn starch is a protein separated from corn (grain) and purified. More preferably, crude yellow corn starch is used. As the starch other than corn starch, soybean, rice bran and the like can be adopted.

【0011】この発明に用いる野菜汁は、野菜の種類を
特に限定したものではないが、できればサポニンまたは
S−アリル−L−システインを含む野菜であることが好
ましい。このような野菜の具体例としては、白菜、キャ
ベツ、ニンジン、薬用ニンジン、パセリ、セロリ、玉ね
ぎなどである。野菜汁は、これらの野菜を圧搾すること
により、絞り出された水分を主成分とする汁であり、こ
れを例えば約120℃で20分程度の高圧滅菌処理を行
なってから培地用基材に添加する。
The vegetable juice used in the present invention is not particularly limited to the kind of vegetable, but it is preferably a vegetable containing saponin or S-allyl-L-cysteine, if possible. Specific examples of such vegetables include Chinese cabbage, cabbage, carrots, medicinal carrots, parsley, celery, and onions. Vegetable juice is a juice whose main component is water squeezed out by squeezing these vegetables. For example, this is subjected to high-pressure sterilization treatment at about 120 ° C. for about 20 minutes before being used as a medium substrate. Added.

【0012】窒素源として用いるイースト(酵母)は、
食品の発酵や醸造に用いることのできる単細胞(真核)
微生物であり、サッカロミセス属などが代表例となるも
のである。窒素源として利用するためのイーストは、死
菌体であってもよく、イーストエキスや乾燥粉末であっ
てもよい。
Yeast used as a nitrogen source is
Single cell (eukaryotic) that can be used for fermentation and brewing of food
It is a microorganism, and the genus Saccharomyces is a typical example. The yeast to be used as the nitrogen source may be dead cells, yeast extract or dry powder.

【0013】上記のように澱粉をアミラーゼで加水分解
した糖化物、野菜汁およびイースト以外にも培地用基材
には、必要に応じて蛋白質や無機塩類などを配合しても
よい。そのような無機塩類としては、塩化カルシウム、
塩化ナトリウム、リン酸ナトリウムなどが挙げられる。
蛋白質としては、大豆蛋白その他の植物性蛋白質などが
挙げられる。
As described above, in addition to the saccharified product obtained by hydrolyzing starch with amylase, vegetable juice and yeast, proteins, inorganic salts and the like may be added to the substrate for the medium, if necessary. Such inorganic salts include calcium chloride,
Examples thereof include sodium chloride and sodium phosphate.
Examples of proteins include soybean protein and other vegetable proteins.

【0014】また、澱粉をアミラーゼで加水分解した糖
化物に対して、さらに糖分を添加することも好ましいこ
とであり、例えばショ糖(グラニュー糖)、グルコース
(ブドウ糖)、水飴などを添加する。
It is also preferable to further add sugar to the saccharified product obtained by hydrolyzing starch with amylase, for example, sucrose (granulated sugar), glucose (dextrose), starch syrup and the like.

【0015】このようにして調整された発酵用培地に接
種する発酵菌は、納豆菌であるバチルス ズブチリス
AKおよび乳酸菌を含む発酵菌である。
The fermenting bacterium inoculated into the fermentation medium thus prepared is Bacillus subtilis which is a natto bacterium.
It is a fermenting bacterium containing AK and lactic acid bacteria.

【0016】バチルス ズブチリス AKは、通常の納
豆菌であるバチルス ズブチリスに対して、紫外線、X
線、高・低温環境(100℃、0℃)、乳酸菌との競
合、芽胞を作りやすい培地[肉エキス5.0、ペプトン
10.0、塩化ナトリウム5.0、寒天15.0、野菜
(キャベツ、ニンジン、セロリ、パセリ)の圧搾汁、配
合割合は全て重量部]などの諸条件を設定し、これらの
過酷な環境や条件下でも死なずに生育する耐性菌を発見
し、その経代培養を繰り返して選抜して得たものであ
る。
[0016] Bacillus subtilis AK can be treated with ultraviolet rays, X, against Bacillus subtilis which is an ordinary natto bacterium.
Line, high / low temperature environment (100 ° C, 0 ° C), competition with lactic acid bacteria, medium that easily forms spores [meat extract 5.0, peptone 10.0, sodium chloride 5.0, agar 15.0, vegetables (cabbage) , Carrots, celery, parsley), and the ratios are all parts by weight], and resistant bacteria that can grow without dying even under these harsh environments and conditions are found, and subcultured. It was obtained by repeatedly selecting.

【0017】上記菌株の菌学的性状は、以下の通りであ
る。 (a) 形態学的性質 細胞の形及び大きさ 棹菌 1.0〜1.2×3.0〜50μm 細胞の多形性の有無 無し 運動性の有無 有り (周毛性の鞭毛) 芽胞の有無 有り 楕円 菌体のほぼ中央 (b) 培養的性質 肉汁寒天平板培養 円形集落 白濁 肉汁液体培養 上部又は下部 菌凝体 (c) 生化学的性質 グラム染色 陽性 硝酸塩の還元 陽性 MRテスト 陰性 VPテスト 陽性 インドールの生成 陰性 硫化水素の生成 陰性 クエン酸の利用 陽性 カタラーゼ 陽性 生育の範囲 pH 5.5〜7.0 温度 25℃〜40℃ この菌株は、独立行政法人産業技術総合研究所に「(受
託番号)FERM P−18291」として寄託されて
いる。
The mycological properties of the above strains are as follows. (a) Morphological properties Cell shape and size Bacteria 1.0 to 1.2 × 3.0 to 50 μm Presence or absence of polymorphism in cells Presence or absence of motility (peripheral flagella) Presence or absence of spores Oval cells Almost middle (b) Culture property Meat broth agar plate culture Round colony White turbid broth liquid culture Upper or lower microbial aggregate (c) Biochemical properties Gram stain Positive nitrate reduction Positive MR test Negative VP test Positive Indole formation Negative hydrogen sulfide Negative Use of citric acid Positive catalase Positive Growth range pH 5.5 to 7.0 Temperature 25 ° C to 40 ° C This strain was deposited at the National Institute of Advanced Industrial Science and Technology as "(deposit number) FERM P-18291" There is.

【0018】この発明に用いる乳酸菌は、乳酸棹菌であ
るラクトバチルス(Lactobacillus)、乳酸球菌である
ストレプトコッカス(Streptococcus)などであり、病
原性のない菌類に限るのは勿論である。
The lactic acid bacteria used in the present invention include Lactobacillus, which is a lactic acid bacillus, and Streptococcus, which is a lactic acid coccus, and it is needless to say that it is not limited to pathogenic fungi.

【0019】この発明で採用することが好ましい発酵条
件は、pH4.5〜6.5、28〜32℃の条件で2ヶ
月以上である。上記より強い酸性域で所定温度未満の条
件では、2ヶ月以上発酵させても、この発明に用いる所
定の納豆菌が効率よく糖および窒素源を資化しないと推
定され、得られた食品に所期した効果が充分得られな
い。上記の酸性域を越えて中性またはアルカリ性の条件
で所定温度を超えて高温では発酵不充分で所定の納豆菌
が効率よく糖および窒素源を資化せず、得られた保健栄
養食品は上記同様に所期した効果が充分得られないもの
になる。
The fermentation conditions preferably used in the present invention are pH 4.5 to 6.5 and 28 to 32 ° C. for 2 months or more. It is presumed that the specified Bacillus natto used in the present invention does not efficiently utilize sugars and nitrogen sources even if fermented for 2 months or more under conditions of stronger acidity than the above and below a predetermined temperature, and the obtained foods have The desired effect cannot be obtained sufficiently. In the neutral or alkaline conditions above the above acidic range and above a predetermined temperature at a high temperature, fermentation is insufficient at a high temperature and the specified Bacillus natto does not efficiently assimilate sugar and nitrogen sources, and the obtained health food is Similarly, the desired effect cannot be obtained sufficiently.

【0020】この発明で採用することが好ましい熟成条
件は、pH4.0〜6.0、13〜17℃で4ヶ月以上
である。上記より強い酸性域で所定温度未満の条件で
は、4ヶ月以上熟成させても、発酵生産物として各種の
活性を有するアミノ酸、リポ蛋白、リポ多糖(リポポリ
サッカライド)、リピッドなどが充分に低分子量化しな
いと推定され、得られた食品に所期した効果が充分得ら
れない。上記の酸性域を越えて中性またはアルカリ性の
条件で所定温度を超えて高温で熟成させても、活性が低
下すると推定され、得られた保健栄養食品は上記同様に
所期した効果が充分得られないものになる。
The aging conditions preferably used in the present invention are pH 4.0 to 6.0 and 13 to 17 ° C. for 4 months or more. In the stronger acidic region and under the temperature lower than a predetermined temperature, amino acids, lipoproteins, lipopolysaccharides (lipopolysaccharides), lipids and the like having various activities as fermentation products have sufficiently low molecular weight even if they are aged for 4 months or more. It is presumed that it does not occur, and the desired effect cannot be obtained on the obtained food. It is presumed that the activity will decrease even if it is aged at a high temperature above a predetermined temperature under a neutral or alkaline condition exceeding the above acidic range, and the health and nutrition food obtained has sufficient expected effects as above. It will not be possible.

【0021】生成した液状成分を分取するには、ろ過ま
たは遠心分離などの周知の分離手段を採用すればよく、
得られた食品用原液は、そのまま利用できるが、必要に
応じて濃縮するか、または希釈して利用することもでき
る。
In order to separate the produced liquid component, well-known separation means such as filtration or centrifugation may be adopted.
The obtained undiluted solution for foods can be used as it is, but can be concentrated or diluted as needed before use.

【0022】因みに、この発明の製造方法で得られる健
康食品は、生命現象を刺激して生体内の諸機能を強化促
進させ、生体の恒常性(Homeostasis)を強固に維持
し、健康の増進を図ることを目的としたものであり、そ
の構成成分としては、生体内酵素合成を容易にするため
の物質、すなわち発酵によって得られる酵素を可逆的に
切断して活性アミノ酸残基としたフラグメントを含み、
その他にビオシチン、メバロン酸、リポ酸、アデニン、
グアニン、シトシン、チミン、ウラシル、エルゴステリ
ン、マンナン(酵母マンナン)のような生体内で活用で
きる有用物質を含有する。このような有用物質は、ベス
レッカ(Besredka)の提唱したアンチビールスの組織活
性因子、フィラトフ(Filatov)の説明する生命源刺激
素を含み、これらを生物化学的反応によって組み合わ
せ、安全かつ有効に作用するように処理した培養濾液で
あると考えられる。
By the way, the health food obtained by the production method of the present invention stimulates life phenomena to enhance and promote various functions in the living body, strongly maintains homeostasis of the living body, and promotes health. It is intended for the purpose of including the substance for facilitating in-vivo enzyme synthesis, that is, the fragment obtained by reversibly cleaving the enzyme obtained by fermentation into an active amino acid residue. ,
In addition, biocytin, mevalonic acid, lipoic acid, adenine,
It contains useful substances that can be utilized in vivo such as guanine, cytosine, thymine, uracil, ergosterin, and mannan (yeast mannan). Such useful substances include an anti-virus tissue-activating factor proposed by Besredka, a life source stimulant described by Filatov, which are combined by a biochemical reaction to act safely and effectively. It is considered to be the culture filtrate treated as above.

【0023】また、培養濾液が発酵過程によって産生す
る酵素を種類毎に以下に例示列挙する。 酸化還元酵素:グルコースオキシダーゼ、カタラー
ゼ、パーオキシダーゼ、チトクロームオキシダーゼ 加水分解酵素:ペクチナーゼ、ペクチンエステラー
ゼ、タンナーゼ、ホスファターゼ、ラクターゼ、インベ
ルターゼ、α−アミラーゼ、β−アミラーゼ、セルラー
ゼ、ヘミセルラーゼ 転移酵素:ヘキソナーゼ、アミノトランスフェラー
ゼ、トランスアルドラーゼ ペプチド加水分解酵素:エキソペプチダーゼ、エン
ドペプチダーゼ、アスペルギロペプチダーゼ、その他の
プロテアーゼ 異性化酵素:ホスホトリオースイソメラーゼ、ホス
ホリボイソメラーゼ、ブドウ糖イソメラーゼ 合成酵素:アセチルCoAリガーゼ リアーゼ:ピルビン酸デカルボキシラーゼ、フマラ
ーゼ、アスパルターゼ
The enzymes produced by the fermentation process in the culture filtrate are listed below by type. Redox enzyme: glucose oxidase, catalase, peroxidase, cytochrome oxidase Hydrolase: pectinase, pectinesterase, tannase, phosphatase, lactase, invertase, α-amylase, β-amylase, cellulase, hemicellulase transferase: hexonase, aminotransferase , Transaldolase Peptide hydrolase: Exopeptidase, Endopeptidase, Aspergillopeptidase, Other proteases Isomerase: Phosphotriose isomerase, Phosphoriboisomerase, Glucose isomerase Synthase: Acetyl CoA ligase Liase: Pyruvate decarboxylase, Fumarase , Aspartase

【0024】[0024]

【実施例】まず、イエローコーンスターチ2.3kg、
大豆ペプトン0.5kg、米糠汁0.5kg、塩化カル
シウム80g、食塩150gに精製水50kgを加え、
加熱して溶解した。次いでこれを冷却し、アミラーゼ4
0gを加えて充分に糖化させた。糖化終了後、グラニュ
ー糖1.5kg、グルコース(ブドウ糖)1.5kg、
酵母エキス450g、水飴1.5kg、リン酸ナトリウ
ム80g、野菜の圧搾汁(キャベツ、ニンジン、セロ
リ、パセリの合計)5kg、および精製水を加えて全量
を150kgにした。
EXAMPLE First, 2.3 kg of yellow cornstarch,
Soybean peptone 0.5 kg, rice bran juice 0.5 kg, calcium chloride 80 g, salt 150 g, purified water 50 kg,
It was heated and dissolved. It is then cooled and amylase 4
0 g was added for sufficient saccharification. After saccharification, 1.5 kg of granulated sugar, 1.5 kg of glucose (glucose),
450 g of yeast extract, 1.5 kg of starch syrup, 80 g of sodium phosphate, 5 kg of vegetable juice (cabbage, carrot, celery, parsley) 5 kg, and purified water were added to bring the total amount to 150 kg.

【0025】そして、水酸化ナトリウムを添加してpH
を7.3〜7.8の範囲内に調整し、これを培養缶に入
れて120℃で20分間高圧滅菌した。これを冷却した
後、バチルス ズブチリス AK株を接種し、温度30
±2℃の恒温室でpH4.5〜6.5で60日間発酵さ
せ、次いで温度15±2℃の恒温室でpH4.0〜6.
0の条件下で180日間熟成させて培養液を透明化させ
た。これをフィルターによってろ過し、125リットル
の液状の保健栄養食品の原液(以下、培養濾液と称す
る。)を得た。
Then, the pH is adjusted by adding sodium hydroxide.
Was adjusted within the range of 7.3 to 7.8, and this was put in a culture can and subjected to high-pressure sterilization at 120 ° C. for 20 minutes. After cooling this, Bacillus subtilis AK strain was inoculated at a temperature of 30
Fermentation is performed in a temperature-controlled room of ± 2 ° C at a pH of 4.5 to 6.5 for 60 days, and then in a temperature-controlled room of 15 ± 2 ° C to a pH of 4.0 to 6.
The culture was clarified by aging it for 180 days under the condition of 0. This was filtered through a filter to obtain 125 liters of liquid stock solution of health food and nutritional food (hereinafter referred to as culture filtrate).

【0026】得られた保健栄養食品原液100g中の一
般分析結果を以下の表1中に示す。なお、表中の記号φ
は、検出限界以下の微量を示している。
The general analysis results in 100 g of the obtained health food and nutritional food concentrate are shown in Table 1 below. The symbol φ in the table
Indicates a trace amount below the detection limit.

【0027】[0027]

【表1】 [Table 1]

【0028】また、上記の培養濾液について、東ソー社
製カラム(TSKgel G2500PWXL)を用い、移動相を
水、アセトニトリルおよびトリフルオロ酢酸の55:45:0.
1混合液とする液体高速クロマトグラム(Shodex社製:
GPC SYSTEM-21)でサイズ排除クロマトグラフィー(SE
C)を測定し、そのときの検出器感度(紫外分光光度計:
mV)を分子量既知の標準品の溶出時間と比較して分析
した分子量分布の図表を図1に示し、この図表における
分子量画分の面積が全体に占める割合(百分率)を表2
に示した。
With respect to the above culture filtrate, a column (TSKgel G2500PWXL) manufactured by Tosoh Corporation was used, and the mobile phase was 55: 45: 0.
High-performance liquid chromatogram for 1 mixture (Shodex:
Size exclusion chromatography (SE on GPC SYSTEM-21)
C) and the detector sensitivity at that time (UV spectrophotometer:
mV) is compared with the elution time of a standard with a known molecular weight, and a diagram of the molecular weight distribution is shown in FIG. 1, and the ratio (percentage) of the area of the molecular weight fraction in this diagram to the whole is shown in Table 2.
It was shown to.

【0029】[0029]

【表2】 [Table 2]

【0030】さらにまた、得られた培養濾液の安全性を
確かめるため、ウィスター系ラットを用いて経口による
急性毒性試験を行なった。その結果については、以下の
通りである。
Furthermore, in order to confirm the safety of the obtained culture filtrate, an oral acute toxicity test was conducted using Wistar rats. The results are as follows.

【0031】4倍濃縮液を給与量換算で雄14.0、4
2ml/kg、雌14.0、42ml/kg(通常量の
10倍または30倍量)を投与しても雄、雌共に死亡例
が認められず、中毒症状もなく、また体重の推移も一般
状態も試験期間中清浄な状態で推移し、血液検査域も正
常域にあった。10ml/kgの投与量は、ラットに対
する投与量としては最高投与量と考えられ、供試品を通
常投与量に換算すると経口LD50値は、雄雌共に4
2.0ml/kg以上と推測された。
A 4 × concentrated solution is converted into a male salary 14.0, 4
Even if 2 ml / kg, female 14.0, 42 ml / kg (10 times or 30 times the usual amount) were administered, neither male nor female died, no intoxication symptoms were observed, and body weight was generally changed. The condition also remained clean during the test period, and the blood test area was in the normal area. The dose of 10 ml / kg is considered to be the highest dose for rats, and when the test sample is converted to the usual dose, the oral LD50 value is 4 for both males and females.
It was estimated to be 2.0 ml / kg or more.

【0032】次に、上記のようにして得られた培養濾液
の抗菌性、高血圧ラットに対する投与の影響、人為的に
誘発した糖尿病ラットに対する投与の影響を調べた。こ
れらの試験方法と結果を以下に示す。
Next, the antibacterial properties of the culture filtrate obtained as described above, the effects of administration on hypertensive rats, and the effects of administration on artificially induced diabetic rats were examined. The test methods and results are shown below.

【0033】[培養濾液の抗菌性]使用菌株およびその
測定用培地は以下の通りである。 (1)エシェリヒア コリ(ATCC25922):DHL寒天培地 (2)サルモネラ エンテリティディス(ATCC25923):DH
L寒天培地 (3)クレブシェラ ニューモニエ(ATCC13883):BTB
培地 菌液調整:トリプトブイヨン30mlに前培養液100
μlを加える。35℃で振とう培養し、適当な吸光度で
培養を止め、105CFU/mlの菌懸濁液10mlとなるよう
にリン酸緩衝液で希釈する。 除菌操作:調製した菌液を3000rpm,15分遠心し、
上清を被検物質と等量で置換後、35℃、2時間振とう
反応させる。また、対照として何も入れていない菌懸濁
液を同じ条件下に置く。 試料の塗布・培養・計数:リン酸緩衝液で段階希釈した
試料100μlをそれぞれの測定用培地2枚にコンラー
ジ棒で塗布し、35℃、48時間培養し、発育したコロ
ニーを計数した。これらの結果は、下記の表3に示し
た。
[Antibacterial Properties of Culture Filtrate] The strains used and the medium for measurement thereof are as follows. (1) Escherichia coli (ATCC25922): DHL agar medium (2) Salmonella Enteritidis (ATCC25923): DH
L agar medium (3) Klebsiella pneumoniae (ATCC13883): BTB
Preparation of culture medium: 30 ml of tryptobroth and 100 preculture liquid
Add μl. The cells are cultivated with shaking at 35 ° C., stopped at an appropriate absorbance, and diluted with a phosphate buffer so as to obtain 10 ml of a bacterial suspension of 10 5 CFU / ml. Sterilization operation: The prepared bacterial solution was centrifuged at 3000 rpm for 15 minutes,
After replacing the supernatant with an equal amount of the test substance, shake reaction is performed at 35 ° C. for 2 hours. As a control, a bacterial suspension containing nothing is placed under the same conditions. Application / culture / counting of sample: 100 μl of a sample serially diluted with a phosphate buffer was applied to 2 sheets of each measuring medium with a conradi stick and cultured at 35 ° C. for 48 hours, and grown colonies were counted. The results are shown in Table 3 below.

【0034】[0034]

【表3】 [Table 3]

【0035】[高血圧ラットに対する投与の影響]5日
間の検疫・訓化期間を置き、健常と判断された雄性の自
然発症高血圧ラット(SHR)、6週令を1群7匹とし
て3群に分け、試験群−1には培養濾液を等倍量、試験
群−2には10倍量、対照群には蒸留水を給水瓶に入
れ、28日間連続して所定の餌と共に自由に摂取させ
た。血圧測定は、週(7日)間隔で同時に行ない、この
結果を表4に示した。
[Effects of Administration on Hypertensive Rats] A male spontaneously hypertensive rat (SHR) judged to be healthy after a quarantine / training period of 5 days was divided into 3 groups with 7 rats aged 6 weeks. , Test group-1 had an equal volume of the culture filtrate, test group-2 had a 10-fold volume, and the control group had distilled water in a water bottle and was allowed to freely ingest with a predetermined feed for 28 consecutive days. . Blood pressure was measured simultaneously at weekly (7 days) intervals, and the results are shown in Table 4.

【0036】[0036]

【表4】 [Table 4]

【0037】表4の結果からも明らかなように、対照群
に比べて培養濾液投与群は、2週間後から上昇抑制を示
した。
As is clear from the results in Table 4, the culture filtrate-administered group showed suppression of increase after 2 weeks as compared with the control group.

【0038】[人為的に誘発した糖尿病ラットに対する
投与の影響]7日間の検疫・訓化期間を置き、健常と判
断された雄性のウィスターST系ラット(6週令)に対
し、ストレプトゾトシンを体重1kg当たり40mgを
尾静脈内に注入し、翌日から血糖値を測定し、血糖値が
ほぼ一定になるように1群5匹を2群に分け、試験群
(a)に14日間培養濾液をヒトの投与量の約10倍量
を給水瓶に入れて経口連続投与した。
[Effect of Administration on Artificially Induced Diabetic Rats] A male Wistar ST strain rat (6 weeks old) judged to be healthy after a quarantine / training period of 7 days was given 1 kg of streptozotocin. Inject 40 mg per tail into the tail vein, measure the blood glucose level from the next day, divide 5 animals into 2 groups so that the blood glucose level will be almost constant, and add the human culture filtrate for 14 days to the test group (a). About 10 times the dose was placed in a water bottle and continuously orally administered.

【0039】[0039]

【表5】 [Table 5]

【0040】表5の結果からも明らかなように、培養濾
液投与群は6日目から僅かな上昇抑制傾向を示した。一
方、対照群(b)は、15日後に約3.5倍の上昇率で
あり、培養濾液投与群より約80%も高い上昇率を示し
た。これらの傾向から、培養濾液投与群は、血糖値上昇
抑制傾向を示し、糖尿病の予防や進行抑制などに良い影
響を与えていることが示唆された。
As is clear from the results in Table 5, the culture filtrate-administered group showed a slight tendency to suppress the increase from the 6th day. On the other hand, the control group (b) had an increase rate of about 3.5 times after 15 days, which was about 80% higher than that of the culture filtrate administration group. From these tendencies, it was suggested that the group to which the culture filtrate was administered showed a tendency to suppress the increase in blood glucose level, and had a good influence on the prevention of diabetes and the suppression of the progression.

【0041】以下に得られた保健栄養食品原液を利用し
て製造した健康飲料、カプセル状健康食品、化粧水、動
植物用栄養剤の配合例を表6〜9に示した。
Tables 6 to 9 show blending examples of health drinks, health foods in capsules, lotions, and nutrients for animals and plants produced by using the stock solutions of health and nutritional foods obtained below.

【0042】健康飲料は、培養濾液8〜16%に表6に
示すような他の原料を配合して調製した。
Health drinks were prepared by mixing 8 to 16% of the culture filtrate with other raw materials as shown in Table 6.

【0043】[0043]

【表6】 [Table 6]

【0044】カプセル状健康食品は、培養濾液を20倍
に濃縮し、表7に示すような他の原料を配合して調製し
た。
The capsule-shaped health food was prepared by concentrating the culture filtrate 20 times and blending other raw materials as shown in Table 7.

【0045】[0045]

【表7】 [Table 7]

【0046】化粧水は、培養濾液8%に表8に示すよう
な他の原料を配合して調整した。
The lotion was prepared by blending 8% of the culture filtrate with other raw materials as shown in Table 8.

【0047】[0047]

【表8】 [Table 8]

【0048】動植物用栄養剤は、培養濾液20%に、表
9に示すその他の原料を配合して調製した。
The nutrient for animals and plants was prepared by mixing 20% of the culture filtrate with the other raw materials shown in Table 9.

【0049】[0049]

【表9】 [Table 9]

【0050】[0050]

【発明の効果】この発明は、以上説明したように、所定
の発酵用培地で所定の納豆菌で効率よく糖および窒素源
を資化させ、さらに所定条件で発酵および熟成させて保
健栄養食品を効率よく製造することができ、特に発酵性
菌類として所定の菌株を採用し、これによって保健作用
をより確実に効率よく液状の保健栄養食品を提供できる
という利点がある。
As described above, the present invention efficiently utilizes sugar and nitrogen sources in a predetermined fermentation medium with a predetermined Bacillus natto, and ferments and ripens them under predetermined conditions to produce a health and nutrition food. It has an advantage that it can be produced efficiently, and in particular, a predetermined strain is adopted as a fermentative fungus, whereby a health action can be more reliably and efficiently provided as a liquid health and nutrition food.

【図面の簡単な説明】[Brief description of drawings]

【図1】サイズ排除クロマトグラフィーにおける検出器
感度(mV)と溶出時間(分)の関係、およびこれから分
析された培養濾液の分子量分布を示す図表
FIG. 1 is a diagram showing the relationship between detector sensitivity (mV) and elution time (minutes) in size exclusion chromatography, and the molecular weight distribution of culture filtrates analyzed from this.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 コーンスターチを含む澱粉をアミラーゼ
で加水分解した糖化物を培地用基材とし、これに野菜汁
および窒素源としてイーストを添加して発酵用培地を調
整し、この培地に納豆菌であるバチルス ズブチリス
AK(FERM P−18291)および乳酸菌を含む
発酵菌を接種し、発酵および熟成させた後、生成した液
状成分を分取して食品用原液とすることからなる保健栄
養食品の製造方法。
1. A saccharified product obtained by hydrolyzing starch containing corn starch with amylase is used as a base material for a medium, and a vegetable juice and yeast as a nitrogen source are added to the medium to prepare a fermentation medium. Bacillus subtilis
A method for producing a health and nutrition food, which comprises inoculating a fermenting bacterium containing AK (FERM P-18291) and lactic acid bacteria, fermenting and aging, and then collecting the produced liquid component to obtain a stock solution for food.
【請求項2】 発酵が、pH4.5〜6.5、28〜3
2℃の条件で2ヶ月以上行なう発酵である請求項1記載
の保健栄養食品の製造方法。
2. Fermentation of pH 4.5-6.5, 28-3
The method for producing a health and nutrition food according to claim 1, wherein the fermentation is carried out at 2 ° C for 2 months or more.
【請求項3】 熟成が、pH4.0〜6.0、13〜1
7℃の条件で4ヶ月以上行なう熟成である請求項1また
は2に記載の保健栄養食品の製造方法。
3. Aging is carried out at pH 4.0 to 6.0, 13 to 1
The method for producing a health and nutrition food according to claim 1 or 2, which is aging at 7 ° C for 4 months or more.
JP2002014512A 2002-01-23 2002-01-23 Manufacturing method of health nutrition food Expired - Fee Related JP3902015B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002014512A JP3902015B2 (en) 2002-01-23 2002-01-23 Manufacturing method of health nutrition food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002014512A JP3902015B2 (en) 2002-01-23 2002-01-23 Manufacturing method of health nutrition food

Publications (2)

Publication Number Publication Date
JP2003210136A true JP2003210136A (en) 2003-07-29
JP3902015B2 JP3902015B2 (en) 2007-04-04

Family

ID=27651166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002014512A Expired - Fee Related JP3902015B2 (en) 2002-01-23 2002-01-23 Manufacturing method of health nutrition food

Country Status (1)

Country Link
JP (1) JP3902015B2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213688A (en) * 2005-02-07 2006-08-17 Toshio Oshiro Nk(natural killer) activity enhancer
WO2008088033A1 (en) * 2007-01-19 2008-07-24 Sueo Wada Hiv-protease inhibitor and method for production thereof
JP2009159853A (en) * 2007-12-28 2009-07-23 Echigo Seika Co Ltd Method for creating low pressure-resistant yeast and method for producing fermented food and fermented food and method for sterilizing fermented food
CN102578584A (en) * 2011-01-12 2012-07-18 松尾理 Food for preventing thrombotic diseases
JP2012175979A (en) * 2012-05-15 2012-09-13 Echigo Seika Co Ltd Method for producing low pressure-resistant yeast, method for producing fermented food, method for stopping fermentation by non-thermal sterilization of fermented food, and fermented food
JP2014079264A (en) * 2014-02-13 2014-05-08 Echigo Seika Co Ltd Method for stopping fermentation of fermented food product by non-heat sterilization
CN103815413A (en) * 2014-03-19 2014-05-28 苏州科大微龙信息技术有限公司 Vital-energy-deficiency body-regulating enzyme and preparation method thereof
JP2015017070A (en) * 2013-07-12 2015-01-29 株式会社エンザミン研究所 Insulin resistance improving agent and health supplement for preventing insulin resistance disorders
WO2016067360A1 (en) * 2014-10-28 2016-05-06 株式会社エンザミン研究所 Insulin resistance-improving agent and health supplement for preventing insulin-resistant diseases
CN109965218A (en) * 2019-03-24 2019-07-05 张学海 A kind of zymotechnique of fruits and vegetables natto

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213688A (en) * 2005-02-07 2006-08-17 Toshio Oshiro Nk(natural killer) activity enhancer
WO2008088033A1 (en) * 2007-01-19 2008-07-24 Sueo Wada Hiv-protease inhibitor and method for production thereof
JP2009159853A (en) * 2007-12-28 2009-07-23 Echigo Seika Co Ltd Method for creating low pressure-resistant yeast and method for producing fermented food and fermented food and method for sterilizing fermented food
CN102578584A (en) * 2011-01-12 2012-07-18 松尾理 Food for preventing thrombotic diseases
JP2012143187A (en) * 2011-01-12 2012-08-02 Osamu Matsuo Thrombotic disease preventing food
JP2012175979A (en) * 2012-05-15 2012-09-13 Echigo Seika Co Ltd Method for producing low pressure-resistant yeast, method for producing fermented food, method for stopping fermentation by non-thermal sterilization of fermented food, and fermented food
JP2015017070A (en) * 2013-07-12 2015-01-29 株式会社エンザミン研究所 Insulin resistance improving agent and health supplement for preventing insulin resistance disorders
JP2014079264A (en) * 2014-02-13 2014-05-08 Echigo Seika Co Ltd Method for stopping fermentation of fermented food product by non-heat sterilization
CN103815413A (en) * 2014-03-19 2014-05-28 苏州科大微龙信息技术有限公司 Vital-energy-deficiency body-regulating enzyme and preparation method thereof
WO2016067360A1 (en) * 2014-10-28 2016-05-06 株式会社エンザミン研究所 Insulin resistance-improving agent and health supplement for preventing insulin-resistant diseases
KR20170071510A (en) * 2014-10-28 2017-06-23 가부시키가이샤 엔자민겡큐쇼 Insulin resistance-improving agent and health supplement for preventing insulin-resistant diseases
CN107073047A (en) * 2014-10-28 2017-08-18 株式会社恩基美研究所 Agent for amelioration of insulin resistance and the healthy accesary foods for preventing insulin resistance disease
CN107073047B (en) * 2014-10-28 2021-08-24 株式会社恩基美研究所 Insulin resistance improving agent
KR102403578B1 (en) * 2014-10-28 2022-05-27 가부시키가이샤 엔자민겡큐쇼 Insulin resistance-improving agent and health supplement for preventing insulin-resistant diseases
CN109965218A (en) * 2019-03-24 2019-07-05 张学海 A kind of zymotechnique of fruits and vegetables natto

Also Published As

Publication number Publication date
JP3902015B2 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
CN105054040B (en) A kind of composition of probiotics fermention ginseng and its preparation method and application
CN109718255B (en) Preparation method of hangover relieving enzyme powder and hangover relieving composition containing the same
CN113413351B (en) Fermented liquid and fermented polypeptide with whitening and anti-aging effects, and preparation methods and applications thereof
CN109182207A (en) One plant has the lactobacillus acidophilus La-SJLH001 for adjusting the prebiotic function such as blood glucose and cholesterol levels and its application
WO2018225557A1 (en) Extracellular polysaccharide of lactic acid bacteria and use thereof
KR102078324B1 (en) Composition for removing hangover and disorders of intestinal comprising grain-origin lactic acid bacteria
JP3902015B2 (en) Manufacturing method of health nutrition food
CN110607256A (en) Lactobacillus reuteri JYLB-131 for improving activity of alcohol dehydrogenase after drinking and application thereof in food and medicine
US20220387532A1 (en) Yeast strain producing glutathione and method of producing glutathione using the same
US11318177B2 (en) Lactobacillus fermentum for treating fructose-related diseases
JP4885611B2 (en) Gamma-aminobutyric acid-containing ginseng fermented product and method for producing the same
JP2019097544A (en) Novel bacteria belonging to bifidobacterium and compositions comprising the same
KR101539820B1 (en) A food for preventing thrombotic diseases
CN115181710B (en) Lactobacillus salivarius B12WU and application thereof
Furuta et al. Utilization of fermented barley extract obtained from a by-product of barley shochu for nisin production
US20220104523A1 (en) Food and beverage products comprising ascomycetes
Muslim et al. Detection of the optimal conditions for inulinase productivity and activity by Acinetobacter baumannii isolated from agricultural rhizosphere soil
CN115595332A (en) Method for preparing tremella fermentation liquor by combining compound enzyme with microbial fermentation
TW201102433A (en) Process for production of γ -aminobutyric acid
CN101508966B (en) Method for preparing manna oligosacchride with zymohydrolysis of konjaku flour
JP4434927B2 (en) Method for producing γ-aminobutyric acid-containing food, and yeast having high γ-aminobutyric acid production ability
JP4719850B2 (en) Bifidobacterium growth-promoting composition
JP6648348B1 (en) Composition for type I allergy
JP2021122241A (en) Novel lactic acid bacteria high-producing gaba and ornithine, and method for producing oral composition using the lactic acid bacteria
KR20210041681A (en) A composition for lowering blood glucose level or blood pressure or for use of antioxidant comprising Rhynchosia nulubilis fermented by a yeast and a method for preparing the composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20051219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20061219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061227

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 3902015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110112

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120112

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120112

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130112

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130112

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140112

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees